Deals in Depth: November 2008
Executive Summary
November 2008 dealmaking highlights: Genzyme's deal for Osiris's stem cell therapeutics Prochymal and Chondrogen topped the alliance list at a pre-commercial value of $730mm, one of the highest this year. J&J's acquisition of biomaterials company Omrix for $438mm was the highest-valued acquisition, outdoing the pharma group M&As, the leaders of which barely reached $50mm. Money invested in pharma increased slightly and again early and late VC dominated; and device financings took a nosedive, decreasing 81% from last month, and mostly comprised of debt.
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.